ABSTRACT
BACKGROUND: Major depressive disorder (MDD) is a disabling mood disorder, and despite a known heritable component, a large meta-analysis of genome-wide association studies revealed no replicable genetic risk variants. Given prior evidence of heterogeneity by age at onset in MDD, we tested whether genome-wide significant risk variants for MDD could be identified in cases subdivided by age at onset.
METHODS: Discovery case-control genome-wide association studies were performed where cases were stratified using increasing/decreasing age-at-onset cutoffs; significant single nucleotide polymorphisms were tested in nine independent replication samples, giving a total sample of 22,158 cases and 133,749 control subjects for subsetting. Polygenic score analysis was used to examine whether differences in shared genetic risk exists between earlier and adult-onset MDD with commonly comorbid disorders of schizophrenia, bipolar disorder, Alzheimer’s disease, and coronary artery disease.
RESULTS: We identified one replicated genome-wide significant locus associated with adult-onset (>27 years) MDD (rs7647854, odds ratio: 1.16, 95% confidence interval: 1.11–1.21, \( p = 5.2 \times 10^{-11} \)). Using polygenic score analyses, we show that earlier-onset MDD is genetically more similar to schizophrenia and bipolar disorder than adult-onset MDD.
CONCLUSIONS: We demonstrate that using additional phenotype data previously collected by genetic studies to tackle phenotypic heterogeneity in MDD can successfully lead to the discovery of genetic risk factor despite reduced sample size. Furthermore, our results suggest that the genetic susceptibility to MDD differs between adult- and earlier-onset MDD, with earlier-onset cases having a greater genetic overlap with schizophrenia and bipolar disorder.

Keywords: Age at onset, GWAS, Heterogeneity, Major depressive disorder, Polygenic scoring, Stratification

http://dx.doi.org/10.1016/j.biopsych.2016.05.010
Major depressive disorder (MDD) is a highly prevalent and heterogeneous disorder (1). With most individuals experiencing recurrent episodes throughout life (2), MDD is now the second leading cause of disability worldwide (3). MDD is defined by low mood and energy, inability to experience enjoyment, changes to eating and sleep patterns, feelings of guilt or worthlessness, and suicidal thoughts (4). Along with excess mortality and increased risk of suicide (5), MDD is associated with worse clinical outcomes when comorbid with health problems such as cardiovascular disease and cancer (6,7). Although the heritability is estimated at 31% to 42% (8), the causal variants remain elusive; a recent large mega-analysis with over 9000 MDD cases failed to identify any replicable associations (9), despite successes in similarly sized studies of schizophrenia (SCZ) and bipolar disorder (BPD) (10,11). This lack of biological markers may be among the causes for the well-established underfunding of research into MDD relative to its economic and health burden (12) and the reported stigmatization of sufferers (13).

However, several differences exist between MDD and other psychiatric disorders in which replicable genetic associations have been identified, including higher prevalence, greater diagnostic uncertainty, lower heritability, and, crucially, increased heterogeneity. One known source of heterogeneity that may contribute substantially is age at onset (AAO). Onset can occur at any stage of life, yet many factors associated with MDD are either age specific or age restricted. These include biological events such as puberty, menopause, and dementia, and environmental risk factors including childhood maltreatment, childbirth, and divorce. Earlier onset is associated with increased risk in first-degree relatives and with higher heritability (14–18). Considerable differences in the transmission of early-versus late-onset MDD have also been reported (19,20), with some studies suggesting the effects of novel genetic risk factors for MDD appearing later in life (21,22).

Here we build on the previous mega-analysis of the Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium (PGC-MDD), using AAO to stratify cases within a sample of 8920 cases and 9521 control subjects, with the goal of reducing heterogeneity. For each of the nine PGC-MDD samples (23–30), cases were ordered by AAO within study and divided into eight groups (octiles). Genome-wide association analysis of cases in these octiles was conducted genome-wide using the same instrument, indicating that the precise setting (study, clinic, country) was important; we therefore chose to order cases by AAO within each study, rather than across studies, or by absolute AAO cutoffs. This strategy will identify genetic variants that were specific to early or late onset, relative to the mean AAO of the recruited cases. For secondary analysis of sex-specific effects, octiles were additionally defined within only male and female subjects for analysis of sex-specific effects, and for recurrent depression that has a higher heritability. These octiles will be referred to as O1 to O8, with O1 representing the earliest onset octile and O8 representing the latest onset octile. The GenRED (Genetics of Recurrent Early-Onset Depression) study only recruited MDD cases with an AAO below 31 years (23). We compared the distribution of AAO in GenRED with other similar studies (STAR*D [Sequenced Treatment Alternatives to Relieve Depression], RADIANT-UK) and estimated that GenRED recruited the youngest cases (82% of all possible MDD cases), with older cases absent from the study (Supplemental Figure S1). GenRED cases were ordered by AAO and assigned to the appropriate octiles O1 to O5, with no cases present in O6 to O8.

Quality Control

Genotyping was described in the supplementary materials in the original analysis (11). All samples were genotyped with SNP arrays of at least 200,000 SNPs. SNPs were removed for missingness >0.02, case-control difference in SNP missingness >0.02, SNP frequency difference from HapMap3 (phase three of the International HapMap Project) >0.15, or deviation...
Genomic Analysis of Age at Onset in Depression

from Hardy–Weinberg equilibrium in control subjects (exact \( p < 1.0 \times 10^{-6} \)). Subjects were removed for excessive missingness (>0.02), for being identical or closely related to any subject in any sample (\( \rho > .2 \) based on common autosomal SNPs), or if there was evidence for diverging ancestry. Ancestry was estimated using multidimensional scaling applied to 8549 SNPs directly genotyped in all samples and in approximate linkage equilibrium. Imputation was performed using Beagle 3.0.440 (31) with the CEU HapMap3 data (32) to impute 1,235,109 autosomal SNP allele dosages. The first 20 ancestry-informative principal components were included as covariates, along with an indicator for each study.

Genome-wide Association Analysis

Genome-wide association analysis was performed in PLINK using logistic regression to test the association between case-control phenotype and imputed SNP dosages under an additive model (33). Genotyping coordinates are given in NCBI Build 36/UCSC hg18 (National Center for Biotechnology Information, Bethesda, MD). Quality control was conducted separately for each sample. To test for SNPs associated with distinct aspects of MDD based on AAO, we performed three hypothesis-driven analyses (Supplemental Figure S2). The first analysis targeted those SNPs associated with early-onset MDD in a series of genome-wide association analyses, initially looking at the earliest onset cases (O1) against all control subjects, then the combined O1 and O2 cases against control subjects, then O1 to O3, etc., until all cases were included. This approach was based on the sequential additions method (34), which was developed to account for a quantitative trait that is measured in cases but not control subjects and provide an estimate of the best phenotype definition for future studies. The second analysis was similarly performed to examine those SNPs associated with later-onset MDD, but reversing the procedure (i.e., first looking at the latest-onset cases [O8] against all control subjects, then O7–O8 against control subjects, then O6–O8, etc., until all cases were included). The third analysis tested whether the extremes of AAO, both early and late, were introducing heterogeneity to the cases excluding O1 to O2 and O7 to O8, leaving those cases with onset within the interquartile range of AAO for each study (O3–O6). We then tested O3 to O6 cases against all control subjects. Each analysis was performed using all cases, male cases only, female cases only, and recurrent cases only. Analyses of all, or almost all, cases (O1–O8, O1–O7, or O2–O8) were used to identify SNPs that reached greatest significance without an AAO-specific effect and so were omitted from further analysis as would have been captured in the primary analysis of this data. In total, 52 genome-wide analyses were performed \( \left[\frac{6 \times 6 + 1}{4}\right] \), making the standard multiple testing threshold of \( p < 5.0 \times 10^{-8} \) for genome-wide significance anticonservative. We applied a Bonferroni correction for 52 analyses to genome-wide significance, which is highly conservative because many analyses were highly correlated. For replication, we selected SNPs with \( p < 9.5 \times 10^{-10} \) in the discovery sample in more than one analysis (either by sex or recurrence or inclusion of octiles); the combination of cases that yielded the greatest significance was chosen as the basis for replication. This analysis strategy uses AAO as a stratifying variable to construct subsets of cases that may be more homogeneous and identify SNPs that are associated with susceptibility to MDD with a restricted AAO; it does not identify SNPs that control MDD AAO, which would require a case-only analysis of AAO as a quantitative trait.

Replication Analysis

Five replication samples used in the primary analysis of this dataset had AAO information available [TwinGene (35), GenREDII/DepGenesNetwork (25), deCODE (9), PsychCoLaus (36), SHIP-LEGEND (Study of Health in Pomerania-Life-Events and Gene-Environment Interaction in Depression) (37)]. The GenPod/NEW-MEDS and Harvard i2b2 studies, which appeared in the replication of the primary analysis of this dataset, did not have AAO data available and were not included. Four new replication studies were available: 1) a collection of samples available through the University of Munster (38,39); 2) a combination of RADIANT cases from Denmark (40), the Danish DEMO and PRISME studies of MDD (41,42), and a set of Danish population control subjects; 3) the CONVERGE (China Oxford and VCU Experimental Research on Genetic Epidemiology) study of MDD cases and control subjects recruited in China (18,43,44); and 4) the Generation Scotland study, which included measures on MDD (45). These are outlined, alongside the definitions of AAO, in Supplemental Methods. Due to the early median AAO in the GenREDII/DepGenesNetwork, an artificial “median” was introduced at age 27 years, based on the median for the discovery samples. Those SNPs that passed our threshold of \( p < 9.5 \times 10^{-10} \) in the discovery sample were tested for association within these nine replication studies. Due to differences in availability of genome-wide genotype data, each study was genotyped and/or imputed separately. A fixed-effect inverse variance based meta-analysis of the replication studies was performed using METAL (46).

Polygenic Analysis

We also examined the association between early- and late-onset MDD and polygenic risk scores for other psychiatric disorders, as this might reflect either shared genetic etiology or phenotypic contamination (47). Polygenic risk scores for schizophrenia (9379 cases and 7736 control subjects) and bipolar disorder (6990 cases and 4820 control subjects) were created by the PGC, using imputed data and removing overlapping control subjects, ensuring that the datasets were completely independent (10,11). Alzheimer’s disease polygenic risk scores were obtained from the GERAD (Genetic and Environmental Risk for Alzheimer’s disease) Consortium (48) and the coronary artery disease scores from the CARDioGRAM Consortium (49). The imputed GERAD sample comprised 3177 cases and 7277 control subjects, and the CARDioGRAM consortium consisted of 22,233 cases and 64,762 control subjects. All four disorders were chosen for their previous genetic and epidemiological evidence of overlap with MDD (50–52).

Polygenic risk scores were calculated for MDD cases and control subjects, summing the number of risk alleles carried, weighted by the natural log of their odds ratio in the original genome-wide association study (GWAS). Score SNPs with low minor allele frequency (<0.02) or in the major histocompatibility complex region were removed, and score datasets were
pruned for linkage disequilibrium using the clumping command in PLINK to remove SNPs within 500 kb and $\rho^2 > .25$ with a more significantly associated SNP. Seven scores were calculated, using a $p$ value threshold ($P_F$) to restrict to the most significant SNPs in their original genome-wide association analysis ($P_F < .01, .05, .1, .2, .3, .4, .5$). Logistic regression was used to test for association between polygenic risk scores and case-control status using four different case-control sets (all MDD cases vs. control subjects, O1–O3 cases vs. control subjects, O6–O8 cases vs. control subjects, and O1–O3 cases vs. O6–O8 cases) with 20 population principal components and study indicators as covariates. We calculated the proportion of variance explained (Nagelkerke’s $R^2$) by subtraction of a full model (covariates + polygenic risk score) from a reduced model (covariates only). The GenRED sample was not included in the analysis as they had no cases within the O6–O8 analysis; the Bonn-Mannheim study was not included in the analysis of Alzheimer’s disease or coronary artery disease due to overlapping control subjects with the respective consortia.

RESULTS

Summary of AAO

After quality control, the sample consisted of 8920 MDD cases with AAO information and 9519 control subjects with a mean 28.9 years (interquartile range: 18, 38) and the mean 28.9 ± 13.64, reflecting the long tail of older onset cases ($\text{Figure 1}$ and Supplemental Figure S3). Median AAO by study ranged from 20 to 37 years (16 for GenRED, which recruited male subjects with a mean of 29.0 compared to female subjects with a mean 28.9). AAO in German samples having a slightly older onset. Mean AAO was lower for recurrent than nonrecurrent cases, 27.1 to 33.0 ($p < .001$, correcting for study and excluding GenRED). AAO was also older for male subjects with a mean of 29.0 compared to females with a mean 26.7 in females subjects ($p < .001$).

Genome-wide Association Analysis

Our analysis of both early- and late-onset octiles and the intermediate median of AAO excluding extreme-AAO cases led to four tests passing our significance cutoff for replication ($p < 9.5 \times 10^{-5}$), all for associations with SNP rs7647854 on chromosome 3. The only genome-wide significant association for this SNP was in the 50% oldest onset cases against all control subjects (O5–O8: $p = 3.4 \times 10^{-11}$) (Supplemental Figures S4 and S5). As a secondary analysis of this SNP, we split cases within our discovery sample into nonoverlapping quartiles and analyzed them against control subjects. This showed a strong association in the oldest quartile (O7–O8: $p = 9.0 \times 10^{-10}$, odds ratio [OR]: 1.37, 95% confidence interval [CI]: 1.23–1.51) (Figure 2), a moderate effect in the third quartile (O5–O6: $p = 2.0 \times 10^{-5}$, OR: 1.23), and no evidence of association in the two youngest quartiles (O1–O2: $p = .07$, OR: 1.09; O3–O4: $p = .30$, OR: 1.08). Furthermore, when the inclusion threshold for AAO and was increased 1 year at a time within each study (until only 100 cases remained), we observed a gradual increase in effect size for rs7647854 in all studies as the analysis was restricted to progressively later onset cases (Supplemental Figure S6). Analysis by sex or recurrence revealed no additional findings.

Replication Analysis

Given the results from our discovery dataset, rs7647854 was taken forward for replication in nine independent studies (Table 1). The SNP was tested for association with oldest half of MDD cases (O5–O8), because this analysis attained the smallest $p$ value in the discovery studies. The SNP was either directly genotyped or imputed at high confidence across all studies (Supplemental Table S1). The SNP was significantly associated with MDD in a meta-analysis of these studies, with a $p$ value of $7.5 \times 10^{-5}$ and an OR of 1.10 (total number of MDD cases = 6107 and total number of control subjects 124,230) (Table 2; Supplemental Figure S5). Meta-analysis of the combined discovery sample with individual replication studies gave a $p$ value of $5.2 \times 10^{-11}$ and an OR of 1.16 (95% CI: 1.11–1.21), surpassing genome-wide significance.

Polygenic Analysis of Comorbid Illnesses

In the PGC-MDD discovery studies, polygenic risk scores for BPD and SCZ were significantly associated with early-onset MDD. Restricting to only early-onset cases (O1–O3) versus control subjects, the amount of phenotypic variability explained (BPD: $R^2 = .41\%$, $p = 1.4 \times 10^{-12}$; SCZ: $R^2 = .67\%$, $p = 3.0 \times 10^{-18}$) was much greater than for later onset (O6–O8) cases (BPD: $R^2 = .16\%$, $p = 1.9 \times 10^{-8}$; SCZ: $R^2 = .14\%$, $p = 3.9 \times 10^{-5}$) (Figure 3). A similar increase in association with late-onset comorbid disorders was not seen. Polygenic risk scores for coronary artery disease from the CARDIoGRAM Consortium (49) were weakly positively associated with MDD, but this was consistent across early and late onset cases, in contrast to BPD and SCZ (coronary artery disease: O1–O3 cases vs. control subjects, $R^2 = .05\%$, $p = .01$; O6–O8 cases vs. control...
subjects, $R^2 = .05\%, p = .01; O1–O3 cases vs. O6–O8 cases, $R^2 \leq .01\%, p = .76$ (Figure 3). No association with MDD status was seen for the scores generated for Alzheimer’s disease from the GERAD Consortium (48) regardless of AAO (O1–O3 cases vs. control subjects, $R^2 < .01\%, p = .868; O6–O8 cases vs. control subjects, $R^2 = .02\%, p = .223; O1–O3 cases vs. O6–O8 cases, $R^2 = .03\%, p = .157$) (Figure 3). Full results from these analyses are available in Supplemental Tables S2 and S3.

Table 1. Summary of MDD Discovery and Replication Cohorts

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Measure of AAO</th>
<th>Cases With AAO</th>
<th>Control Subjects</th>
<th>Median AAO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discovery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NESDA/NTR (GAIN)</td>
<td>The Netherlands</td>
<td>CIDI</td>
<td>1675</td>
<td>1765</td>
<td>25</td>
</tr>
<tr>
<td>GenRED</td>
<td>United States</td>
<td>DIGS</td>
<td>1020</td>
<td>1253</td>
<td>16</td>
</tr>
<tr>
<td>GSK</td>
<td>Germany</td>
<td>SCAN</td>
<td>887</td>
<td>864</td>
<td>36</td>
</tr>
<tr>
<td>MDD2000-QIMR_610</td>
<td>Australia</td>
<td>CIDI/SSAGA</td>
<td>432</td>
<td>751</td>
<td>26</td>
</tr>
<tr>
<td>MDD2000-QIMR_317</td>
<td>Australia</td>
<td>CIDI/SSAGA</td>
<td>1015</td>
<td>960</td>
<td>26</td>
</tr>
<tr>
<td>MPIP</td>
<td>Germany</td>
<td>Asked at interview</td>
<td>373</td>
<td>537</td>
<td>37</td>
</tr>
<tr>
<td>RADIANT Bonn/Mannheim</td>
<td>Germany</td>
<td>SCAN</td>
<td>883</td>
<td>1290</td>
<td>33</td>
</tr>
<tr>
<td>RADIANT</td>
<td>United Kingdom</td>
<td>SCAN</td>
<td>1407</td>
<td>1588</td>
<td>20</td>
</tr>
<tr>
<td>STAR'D</td>
<td>United States</td>
<td>Asked at interview</td>
<td>1228</td>
<td>511</td>
<td>21</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>8920</td>
<td>9519</td>
<td>33</td>
</tr>
<tr>
<td>Replication</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TwinGene</td>
<td>Sweden</td>
<td>SALT</td>
<td>1009</td>
<td>8601</td>
<td>40</td>
</tr>
<tr>
<td>PsyCoLaus</td>
<td>Switzerland</td>
<td>DIGS</td>
<td>1358</td>
<td>1687</td>
<td>33</td>
</tr>
<tr>
<td>SHIP-LEGEND</td>
<td>Germany</td>
<td>M-CIDI</td>
<td>381</td>
<td>1827</td>
<td>37</td>
</tr>
<tr>
<td>GenRED2/DepGenesNetworks</td>
<td>United States</td>
<td>DIGS</td>
<td>1296</td>
<td>930</td>
<td>17</td>
</tr>
<tr>
<td>University of Münster</td>
<td>Germany</td>
<td>SCID</td>
<td>402</td>
<td>516</td>
<td>27</td>
</tr>
<tr>
<td>Combined Danish sample</td>
<td>Denmark</td>
<td>SCAN</td>
<td>461</td>
<td>1197</td>
<td>31</td>
</tr>
<tr>
<td>CONVERGE</td>
<td>China</td>
<td></td>
<td>5715</td>
<td>5537</td>
<td>34</td>
</tr>
<tr>
<td>deCODE</td>
<td>Iceland</td>
<td>Hospital records</td>
<td>1005</td>
<td>99,175</td>
<td>39</td>
</tr>
<tr>
<td>Generation Scotland</td>
<td>United Kingdom</td>
<td>SCID</td>
<td>1611</td>
<td>4760</td>
<td>30</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>13,238</td>
<td>124,230</td>
<td>30</td>
</tr>
</tbody>
</table>

AAO, age at onset; CONVERGE, China Oxford and VCU Experimental Research on Genetic Epidemiology; CIDI, Composite International Diagnostic Interview; DIGS, Diagnostic Interview for Genetic Studies; GAIN, Genetic Association Information Network; GenRED, Genetics of Recurrent Early-Onset Depression; GSK, GlaxoSmithKline; M-CIDI, Munich–Composite International Diagnostic Interview; MDD, major depressive disorder; MPIP, Max Planck Institute of Psychiatry; NESDA, Netherlands Study of Depression and Anxiety; NTR, Netherlands Twin Register; SALT, Screening Across the Lifespan Twin; SCAN, Schedules for Clinical Assessment in Neuropsychiatry; SCID, Structured Clinical Interview for DSM Disorders; SHIP-LEGEND, Study of Health in Pomerania–Life-Events and Gene-Environment Interaction in Depression; SSAGA, Semi-Structured Assessment for the Genetics of Alcoholism; STAR'D, Sequenced Treatment Alternatives to Relieve Depression.
Supplementary Table S3. All results reported are for the oldest half of MDD cases (O5-8), which had the strongest evidence for association in the discovery study.

CI, confidence interval; MDD, major depressive disorder; OR, odds ratio.

DISCUSSION

Our analysis of AAO and the genetic architecture of MDD suggested that AAO-specific genetic risk factors exist. Unexpectedly, the strongest associations we observed were with the oldest half of MDD cases, where previous analyses have focused on early-onset MDD, supported by studies of the genetic epidemiology of MDD. We emphasize that here “late”-onset MDD was at still a relatively young age (median onset of MDD was at age 27 years with 98% of our sample having onset before 60 years) rather than onset in old age. It is clearer to conceptualize later-onset cases here as “adult-onset” cases, and we recommend that this subgroup should be included in recruitment of future genetic studies, especially as no difference in the heritability captured by SNPs was observed for this subtype compared with early-onset cases (see Supplemental Table S3). However, substantial differences in AAO across studies make it difficult to put a precise age cutoff for this recommended adult-onset MDD.

We show significant association with rs7647854 on chromosome 3, which was associated with the 50% latest-onset cases (OR: 1.16, p = 5.2 x 10^{-11}). This SNP was identified as the second strongest association in the primary mega-analysis of the PGC-MDD dataset (6), though at a much lower significance, and did not replicate (discovery p = 6.5 x 10^{-7}, replication p = .67). Stratifying by AAO leads to much stronger associations in both the discovery and replication samples, despite the reduced sample size. Although analyzing across multiple overlapping AAO subtypes runs the risk of overfitting to maximize significance, we observed highly significant associations for this SNP in both discovery and replication samples. Furthermore, we also observed a gradual increase in effect size as both raw AAO within studies and AAO percentile across studies increased (Figure 2, Supplemental Figure S4). That this was seen both for raw AAO within studies and as a percentile, and in both European and Chinese ancestry studies across a wide variety of AAO measurement tools, suggests that whereas our cutoff of the 50% latest onset cases is arbitrary, the effect exists regardless of exact cutoff used. However, this does not rule out the possibility that AAO may be a proxy for a more homogenous subgroup of MDD based on another factor (e.g., an age-specific environmental trigger or distinct pattern of symptoms with onset later in life). That median AAO and effect size across studies was not significantly correlated (r = .011, p = .88) despite greater effect sizes by AAO percentile within studies suggests that differences in measurement of AAO across studies might obscure effects.

rs7647854 is intergenic, with flanking genes including C3orf70, VPS8, EHHADH, and MAP3K13. C3orf70, VPS8, and MAP3K13 all show evidence of expression in the brain in several areas of potential interest for MDD including the hypothalamus, frontal cortex, pituitary, and thyroid (GTEx; http://www.gtexportal.org) (53). VPS8 and MAP3K13 also show a slight increase in RNA expression within various brain regions during neonatal development (Human Brain Transcriptome: http://hbatlas.org) (54) with maintained expression into adulthood.

This genetic association arises with the supposedly less heritable form of adult-onset MDD, although such summary measures give no information on the effect sizes of individual SNPs. One potential explanation is greater contamination of early-onset MDD cases by individuals misclassified with MDD or having comorbid disorders. Longitudinal studies show that early-onset depressive symptoms predict not only adult depression but also psychosis [e.g., (55)], and there is significantly genetic overlap between MDD and other psychiatric disorders (56). Inclusion of early-onset cases with individuals who will later develop SCZ or BPD would reduce the power of GWASs for MDD, though secondary analysis of age at interview did not support this (Supplemental Figure S7). The polygenic risk score results show that early- and adult-onset MDD cases differ in their genetic susceptibility to BPD and SCZ and suggest that some of the heterogeneity in MDD results from the inclusion of early-onset cases with a greater genetic overlap or misclassification with these disorders. We did not observe a similar pattern of association for two disorders that are often comorbid with late-onset MDD, Alzheimer’s disease, and coronary artery disease (51,52). We did, however, show for the first time a genetic overlap between MDD and coronary artery disease irrespective of AAO but no overlap between MDD and Alzheimer’s disease. We also found that the heritability explained by SNPs across the genome for early- and late-onset MDD did not significantly differ, suggesting, for common variants at least, that recruiting only early-onset cases would not increase power (Supplemental Table S3).

The limitations of our approach are the reduced sample size and multiple testing from stratifying cases into subtypes, and requiring potentially less reliable secondary phenotypes to be widely collected. Measures such as AAO rely on self-report and are often assessed differently across studies, which can be problematic for comparison. The analyses presented here addressed this by analyzing AAO relative to the median of a study, though this assumed that each study recruited cases from the same distribution of onset with observed differences due to how AAO was defined. Furthermore, the effect of our genome-wide associated SNP were consistent in the replication studies, ethnicities, and countries, suggesting that differences in measurement may not be as much of a limitation as expected, at least in the case of AAO in MDD. The other disadvantage of looking at more homogeneous groups is the reduction in sample size. However, it has previously been shown that only modest increases in effect size may be required to offset the reduction in power from analyzing fewer cases, implying that analyses of more homogenous subgroups have the potential to identify novel associations (56).

Our study illustrates the value of using additional phenotypic information on cases in GWASs. We show here that including information on AAO increases the power to detect

<table>
<thead>
<tr>
<th>Study</th>
<th>MDD Cases, n</th>
<th>Control Subjects, n</th>
<th>OR (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discovery</td>
<td>3869</td>
<td>9519</td>
<td>1.30 (1.20–1.40)</td>
<td>3.4 x 10^{-11}</td>
</tr>
<tr>
<td>Replication</td>
<td>6107</td>
<td>124,230</td>
<td>1.10 (1.05–1.17)</td>
<td>7.5 x 10^{-4}</td>
</tr>
<tr>
<td>Meta-analysis</td>
<td>9976</td>
<td>133,749</td>
<td>1.16 (1.11–1.21)</td>
<td>5.2 x 10^{-11}</td>
</tr>
</tbody>
</table>
Figure 3. Polygenic risk profile scoring analysis of bipolar disorder, schizophrenia, Alzheimer’s disease, and coronary artery disease within the major depressive disorder (MDD) discovery studies (excluding GenRED [Genetics of Recurrent Early-Onset Depression]). We calculated the proportion of variance explained (Nagelkerke’s $R^2$) by subtraction of a full model (covariates + polygenic risk score) from a reduced model (covariates only). AAO, age at onset; O, octile; PGC, Psychiatric Genomics Consortium.
associations with MDD, and that analyzing polygenic risk scores from related diseases enables us to identify sources of phenotypic heterogeneity that may have hampered previous genetic studies. In contrast to other approaches that weight cases on AAO (57), our stratification of cases on AAO is agnostic to the direction of the phenotypic effect. Our approach uses the additional phenotype data previously collected by genetic studies and complements an alternative emphasis on collecting large sample sizes through minimal phenotyping. Both strategies will undoubtedly be necessary to identify and characterize different components of the genetic architecture of psychiatric disorders. Furthermore, our analysis shows that tackling phenotypic heterogeneity in MDD can successfully lead to the discovery of a genetic risk factor despite reduced sample size. The identification here of a novel genetic risk variant for MDD is of great importance due to both the scarcity of evidence for the underlying biology and its pressing economic health burden.

ACKNOWLEDGMENTS AND DISCLOSURES

The PGC was funded by National Institute of Mental Health (NIMH) Grant Nos. MH085520 (to PFS) and MH086403. Statistical analyses were carried out on the Genetic Cluster Computer (http://www.geneticcluster.org) hosted by SURF(parser) and financially supported by the Netherlands Scientific Organization Grant No. NWO 480-05-003 (to D. Posthuma) and the department of Psychology, Vrije Universiteit Amsterdam along with a supplement from the Dutch Brain Foundation. The Bonn/Mannheim GWAS was supported by the German Federal Ministry of Education and Research (BMBF) through the Integrated Genome Research Network Systematic Investigation of the Molecular Causes of Major Mood Disorders and Schizophrenia Grant Nos. 01GS08144 and 01GS08147, under the auspices of the National Genome Research Network plus, and through the Integrated Network Integrated Understanding of Causes and Mechanisms in Mental Disorders, under the auspices of the eMed Programme Grant Nos. 01ZX1314A and 01ZX1314G. The Bonn/Mannheim GWAS was also supported by the German Research Foundation (DFG) Grant Nos. FOR2107, RB08/11-1, and NO246/10-1. The GenRED GWAS project was supported by NIMH R01 Grant Nos. MH061686 (to DFL), MH059542 (to W.H. Coryell), MH075131 (W.B. Lawson), MH059552 (UBP), MH059541 (W.A. Scheffner), and MH060912 (MMW). Max Planck Institute of Psychiatry MARS study was supported by the BMBF Program Molecular Diagnostics: Validation of Biomarkers for Diagnosis and Outcome in Major Depression by Grant No. 01ES0811. Genotyping was supported by the Bavarian Ministry of Commerce, and the BMBF in the framework of the National Genome Research Network by Grant Nos. NGFN2 and NGFN-Plus, FKZ 01GS0481 and 01GS08145. The Netherlands Study of Depression and Anxiety and the Netherlands Twin Register contributed to Genetic Association Information Network (GAIN)-MDD and to MDD2000. Funding for NTR/NESDA was provided by the following: the Netherlands Organization for Scientific Research (MagWZonMW) Grant Nos. 904-61-090, 985-10-002, 904-61-193, 480-04-004, 400-05-717, 912-100-20; Spinozaspemie Grant No. 56-464-14192; Geestkracht program Grant No. 10-000-1002; the Center for Medical Systems Biology (NWO Genomics), Biobanking and Biomolecular Resources Research Infrastructure, Vrije Universiteit’s Institutes for Health and Care Research and Neuroscience Campus Amsterdam, BIC/BioAssist/RK (Grant No. 2008.02.14); the European Science Foundation (Grant No. EU/QLRT-2001-01254); the European Community’s Seventh Framework Program (Grant No. FP7/2007-2013); ENGAGE (Grant No. HEALTH-F4-2007-21413); and the European Science Council (Grant No. ERC 230374). Genotyping was funded in part by the GAIN of the Foundation for the US National Institutes of Health, and analysis was supported by grants from GAIN and the NIMH (Grant No. MH081802). Funding for the QIMR samples was provided by the Australian National Health and Medical Research Council (Grant Nos. 214194, 388462, 388927, 388870, 388981, 388982, 399999, 424270, 426611, 496675, 496679, 552485, 552498, 613602, 613606, 613674, 619667), the Australian Research Council (Grant Nos. FT0991360, FT0991022), the FP-5 GenomEUtwin Project (Grant No. QLG2-CT-2002-01254), and the US National Institutes of Health (Grant Nos. AA07535, AA10248, AA13320, AA13321, AA13326, AA14041, MH66206, DA12854, DA01995), and the Center for Inherited Disease Research (Baltimore, MD). RADIANT was funded by the following: a joint grant from the UK Medical Research Council and GlaxoSmithKline (Grant No. Q0701420); the National Institute for Health Research Specialist Biomedical Research Centre for Mental Health at the South London and Maudsley National Health Service Foundation Trust and the Institute of Psychiatry, King’s College London; the UK Medical Research Council (Grant No. G0000647), and the Marie Curie Industry-Academia Partnership and Pathways (Grant No. 286213). The GENDEP study was funded by a European Commission Framework 6 grant (EC Contract Ref.: LSHB-CT-2003-503428). Genotyping of STAR*D was supported by NIMH Grant No. MH072862 (to SPH). STAR*D was funded by NIMH Grant No. N01MH090033 to the University of Texas Southwestern Medical Center at Dallas (to A.J. Rush). The CoLaus/PsyCoLaus study was supported by research grants from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, and the Swiss National Science Foundation (Grant Nos. 3200BO-105993, 3200BO-118308, 33CSCO-122861, 33C3S0-139468, 33CS3S0-148401) and two grants from GlaxoSmithKline Clinical Genetics. SHIP is a part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (Grant Nos. 01ZZ9603, 01ZZ0103, 01ZZ0403), the Ministry of Cultural Affairs, and the Social Ministry of the Federal State of Mecklenburg–West Pomerania. Genome-wide data have been supported by the Federal Ministry of Education and Research (Grant No. SC2K012) and a joint grant from Siemens Healthcare, Erlangen, Germany, and the Federal State of Mecklenburg–West Pomerania. SHIP-LEGEND is funded by the DFG (Grant No. GR 1912/5-1). The TwinGene study was supported by the Swedish Ministry for Higher Education, the Swedish Research Council (Grant No. M-2005-1112), GenomEUtwin (Grant Nos. EU/QLRT-2001-01254, QLQ2-CT-2002-01254), the Swedish Foundation for Strategic Research and the US National Institutes of Health (Grant No. U01 DK066134). The collection of PRISME control subjects and genotyping of the 883 Danish control subjects was supported by grants from The Danish Strategic Research Council, The Stanley Research Foundation, and H. Lundbeck A/S. The Muenster Depression cohorts were supported by the European Union (Grant No. N Health-F2-2008-222983) and by grants from the DFG (Grant Nos. FOR 2107 and DA1151/5-1 [to UD]). Innovative Medizinische Forschung of the Medical Faculty of Munster (Grant Nos. DA129903, DA111107, and DA211012 [all to UD]). Generation Scotland is supported by a Wellcome Trust Strategic Award “Stratifying Resilience and Depression Longitudinally” (Reference No.: 104036/2/14/Z) and core support from the Chief Scientist Office of the Scottish Government Health Directorates (Grant No. C2D/16/6) and the Scottish Funding Council (Grant No. HR03008).

The NIMH Cell Repository at Rutgers University and the NIMH Center for Collaborative Genetic Studies on Mental Disorders made essential contributions to this project. Genotyping was carried out by the Broad Institute Center for Genotyping and Analysis with support from Grant No. U54 RR020278 (which partially subsidized the genotyping of the GenRED cases). Collection and quality control analyses of the control dataset were supported by grants from NIMH and the National Alliance for Research on Schizophrenia and Depression.

We acknowledge the contributions of Dr. George S Zubenko and Dr. Wendy N Zubenko, Department of Psychiatry, University of Pittsburgh School of Medicine, to the GenRED I project. We are grateful to Knowledge Networks (Menlo Park, CA) for assistance in collecting the control dataset. We express our profound appreciation to the families who participated in this project, and to the many clinicians who facilitated the referral of participants to the study. We thank the twins and their families registered at the Australian Twin Registry for their participation in the many studies that have contributed to this research. We thank V. Mooser, G. Weaber, and P. Vollenweider who initiated the CoLaus project. We express our gratitude to the Lausanne inhabitants who volunteered to participate in the PsyCoLaus study. We would like to acknowledge the PRISME-study group, Denmark, for collection of the PRISME samples. We thank David M. Hougaard, Section of Neonatal Screening and Hormones, Statens Serum Institute, Copenhagen, Denmark; Preben Bo Mortensen, National Centre for Register-based Research, Aarhus University, Denmark; Merete Nordentoft,
Mental Health Centre, Copenhagen, Denmark; and The Lundbeck Foundation Initiative for Integrative Psychiatric Research, IPSYCH, Denmark. Funding from the BBSRC and MRC is gratefully acknowledged.

Data used in the preparation of this article were obtained from the Genetic and Environmental Risk for Alzheimer’s disease (GERAD1) Consortium. As such, the investigators within the GERAD1 consortia contributed to the design and implementation of GERAD1 and/or provided data but did not participate in analysis or writing of this report.

SS, HS, KS, and TET are employees of deCODE Genetics/Armena. VA received funds from the German Federal Ministry of Education and Research, from the European Union (FP 7), and from the Interdisciplinary Center for Clinical Research Münster, and he has served on the advisory boards of, or has given presentations on behalf of the following companies: Astra-Zeneca, Janssen-Organon, Lilly, Lundbeck, Servier, Pfizer, Otsuka, and Trommsdorff. BTB has received funding from the National Health and Medical Research Council Australia and honoraria from Lundbeck, Bristol-Myers Squibb, Sanofi, Servier, Astra-Zeneca, Pfizer. UJD is supported by the MRC-BBSRC, Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (Grant No. MR/K026992/1). HJG has received funding from German Research Foundation and Federal Ministry of Education and Research Germany and speakers honoraria from Eli Lilly and Servier. CH acknowledges support from the Medical Research Council (MRC) and the Biotechnology and Biological Sciences Research Council (BBSRC). DJM is supported by an NRS Career Fellowship, funded by the Chief Scientist Office. AMM is supported by a Scottish Funding Council Senior Clinical Fellowship and by the Dame Theresa and Mortimer Sackler Foundation and has received research support from Pfizer, Janssen, and Lilly. CMM was supported by the Netherlands Organization for Scientific Research (Grant No. NOW VENI 916-76-125). BM-M has consulted for Affectis Pharmaceuticals. MP has served on the advisory boards of Lundbeck and Eli Lilly.

All other authors report no biomedical financial interests or potential conflicts of interest.

ARTICLE INFORMATION

From the Institute of Psychiatry, Psychology, and Neuroscience (RAP, IWC, MR, GB, CML), King’s College London, London; Medical Research Council Centre for Neuropsychiatric Genetics and Genomics (KET, NC, MJO), Institute of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, United Kingdom; Lundbeck Foundation Initiative for Integrative Psychiatric Research (HNB, DAB, JG, OM), IPSYCH; Translational Neuropsychiatry Unit (HNB), Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Discipline of Psychiatry (SC-W, BTB), School of Medicine, University of Adelaide, Adelaide, Australia; Department of Psychiatry (TB), Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, Virginia; Division of Psychiatry (LSH, DJM, AMM), University of Edinburgh, Edinburgh, United Kingdom; Institute of Social and Preventive Medicine (ZK), Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Queens-Buffalo School of Medicine (SIS), Group Health, Seattle, Washington; Standley Center for Psychiatric Research (SR), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge; Analytic and Translational Genetics Unit (SR), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; Department of Psychiatry and Psychotherapy (SR), Charité, Campus Mitte, Berlin, Germany; deCODE Genetics (SS, HS, KS, TET), Reykjavik, Iceland; Institute for Community Medicine (AT), University Medicine Greifswald, Greifswald, Germany; Department of Medical Epidemiology and Biostatistics (AV, MLand, PL, PKEM, PFS), Karolinska Institutet, Stockholm, Sweden; Department of Psychiatry and Psychotherapy (VA, UD), University of Muenster, Muenster, Germany; Department of Biological Psychology (DIB, JJH, CMM), EMGO Institute for Health and Care Research and Neuroscience Campus Amsterdam, Vrije Universiteit, Amsterdam, The Netherlands.; Department of Psychology and Psychotherapy (HJG, SVA), University Medicine Greifswald, Greifswald, Germany; Department of Psychiatry (SPH), Kaiser Permanente San Francisco Medical Center, San Francisco, California; Medical Genetics Section (CH, DJP, PT), Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; Department of Psychiatry (ACH, PM), Washington University St. Louis, St. Louis, Missouri; Division of Applied Health Sciences (LJH), University of Aberdeen, Aberdeen, United Kingdom; Interfaculty Institute for Genetics and Functional Genomics (GH), University of Greifswald, Greifswald; Max Planck Institute of Psychiatry (SK, SL, BM-M), Munich, Germany; Mental Health Center Copenhagen (JK), Mental Health Services in Capital Region, University of Copenhagen, Copenhagen, Denmark; Institute of Neuroscience and Physiology (MLand), University of Gothenburg, Gothenburg, Sweden; Department of Genetic Epidemiology in Psychiatry (MLang, JSJ), Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany; Department of Psychiatry and Behavioral Sciences (DFL), Stanford University, Stanford, California; Department of Psychiatry (YM, BWJHP, JHS), EMGO Institute for Health and Care Research and Neuroscience Campus Amsterdam, Vrije Universiteit Medical Center, Amsterdam, The Netherlands; Psychosis Research Unit (OM), Aarhus University Hospital, Risskov, Denmark; Munich Cluster for Systems Neurology (BM-M), Munich, Germany; Institute of Translational Medicine (BM-M), University of Liverpool, Liverpool, United Kingdom; Institute of Health and Biomedical Innovation (DRN), Queensland University of Technology, Brisbane, Queensland, Australia; Therapeia (HO), Reykjavik, Iceland; Institute of Cardiovascular and Medical Sciences (SP), University of Glasgow, Glasgow, United Kingdom; Charles E. Schmidt College of Medicine (MLP), Florida Atlantic University, Boca Raton, Florida; Department of Psychiatry (JPB), University of Iowa Carver College of Medicine, Iowa City, Iowa; Centro de Investigación Biomédica en Red de Salud Mental–Universidad de Granada e Instituto de Investigación Biomédica Sanitaria ibs (MR), Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain; Division of Cancer Epidemiology and Genetics (JSi), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Department of Psychiatry (SIS), Group Health, Seattle, Washington; Faculty of Medicine, University of Iceland (ES); Department of Psychiatry (ES), Landspitali University Hospital, Reykjavik, Iceland; Division of Population Health Sciences (BHS), University of Dundee, Dundee, United Kingdom; Department of Genetics (PFS), University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; and College of Physicians and Surgeons of the Mailman School of Public Health (MMW), Columbia University and New York State Psychiatric Institute, New York, New York.

See the Supplement for full lists of CONVERGE authors, CARDioGRAM authors, and GERAD1 investigators.

RAP and KET contributed equally to this work.

Address correspondence to Cathryn M. Lewis, Ph.D., Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London SE5 8AF, United Kingdom; E-mail: cathryn.lewis@kcl.ac.uk.

Received Dec 1, 2015; revised Mar 26, 2016; accepted May 5, 2016.

Supplementary material cited in this article is available online at http://dx.doi.org/10.1016/j.biopsych.2016.05.010.

REFERENCES


Genomic Analysis of Age at Onset in Depression


